Program
Spironolactone
Also written as “Spironolactone Oral Suspension”, “Torsemide and Spironolactone tablet” and “Torsemide Tablets and Spironolactone Tablets”.
Its studies are mostly in Fibrosis · Heart Failure, led by 5 companies.
Drug pageSpironolactone: every studyMany companies study it; this page follows only the 7 they lead. All 174 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CMP Developmentits history only | 21 open or running | phase 4since Aug 28, 2023 | Feb 16, 2019 | Jun 2028phase 4 · NCT06021860 |
| Sarfez Pharmaceuticalsits history only | 20 open or running | phase 3since Jun 3, 2025 | Jun 3, 2025 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 10 open or running | phase 1since Mar 8, 2010 | Mar 8, 2010 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since Jan 2, 2024 | Jan 2, 2024 | none ahead |
| SPH Sine Pharmaceutical Laboratories | 10 open or running | phase 1since Aug 26, 2024 | Aug 26, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of SPH Sine Pharmaceutical Laboratories only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 26, 2024First study: phase 1 study in Bioequivalence StudyFirst studyNCT06579053 · 64 enrolled · China
TargetBeta
“Mineralocorticoid receptor antagonist”ChEMBL 37, by rule
Other programs on NR3C2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| finerenonerule | Bayer | phase 4 | 25 |
| drospirenonerule | estetra | phase 4 | 20 |
| balcinrenonerule | AstraZeneca | phase 3 | 15 |
| HRS-1780 | Jiangsu HengRui Medicine | phase 3 | 7 |
Studies
The one study SPH Sine Pharmaceutical Laboratories leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06579053Bioequivalence Study · China | 1 | Completed | May 5, 2023 | 64 |
How it is read
Names in the registry
- “Spironolactone”, 4 entries
- “Spironolactone Oral Suspension”, 1 entry
- “Torsemide and Spironolactone tablet”, 1 entry
- “Torsemide Tablets and Spironolactone Tablets”, 1 entry
- “25 mg Aldactone (Spironolactone) tablet”, 1 entry
Conditions, from the studies’ own filings
- Fibrosis, 1 study
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.